Placebo News and Research

RSS

Interventional endovascular therapy is safe but does not improve MS outcomes: Study

The first controlled clinical trial to test the safety and efficacy of interventional endovascular therapy on the symptoms and progression of multiple sclerosis has found that the intervention, sometimes called the "liberation treatment," which has attracted intense interest in the global MS community, does not improve patient outcomes. In a few cases, the treatment made symptoms worse.

16 Mar 2013

Luminex collaborates with Merck to design companion diagnostic device for Alzheimer’s disease

WHITEHOUSE STATION known as MSD outside the United States and Canada, and Luminex Corporation have signed a collaboration and license agreement to develop a companion diagnostic device that will be evaluated to help screen patients for recruitment into Merck's clinical development program for MK-8931, a novel oral beta amyloid precursor protein site cleaving enzyme (BACE) inhibitor and Merck's lead investigational candidate for Alzheimer's disease (AD).

From Luminex 15 Mar 2013

Promising studies for Parkinson's to be presented at 65th AAN meeting

Three studies released today present possible positive news for people with Parkinson's disease. The studies, which will be presented at the American Academy of Neurology's 65th Annual Meeting in San Diego, March 16 to 23, 2013, report on treatments for blood pressure problems, the wearing-off that can occur when people have taken the main drug for Parkinson's for a long time, and for people early in the disease whose symptoms are not well-controlled by their main drugs.

15 Mar 2013

Researchers show inhibiting brain's filter can boost performance for tasks

The brain's prefrontal cortex is thought to be the seat of cognitive control, working as a kind of filter that keeps irrelevant thoughts, perceptions and memories from interfering with a task at hand.

15 Mar 2013

Results from GTx's Phase 2 clinical trial of enobosarm published online

GTx, Inc. today announced that the journal, The Lancet Oncology, has published online ahead of its April print edition the results from GTx's randomized, double-blind, placebo-controlled Phase 2 clinical trial of enobosarm to assess its effects on muscle wasting and physical function in patients with cancer.

15 Mar 2013

Phase 1b study of olesoxime initiated in multiple sclerosis (MS) patients

...

14 Mar 2013

Researchers show vitamin D supplementation may help African-Americans lower blood pressure

High blood pressure, a risk factor for heart attacks, heart failure and stroke, is 40 percent more common in African-Americans than in other American ethnic groups.

14 Mar 2013

ASTRONAUT trial finds no beneficial effects of aliskiren in recently hospitalized heart failure patients

Despite high hopes that a blood pressure-lowering medication called aliskiren would help people following hospitalization for heart failure, no beneficial effects were found, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.

13 Mar 2013

Eplerenone may also reduce risk of heart failure, shows REMINDER trial

The prescription drug eplerenone appears to reduce the risk of cardiovascular mortality and heart failure after a heart attack by more than one-third, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.

13 Mar 2013

Research findings could lead to new sleep therapies to improve memory disorders

A team of sleep researchers led by UC Riverside psychologist Sara C. Mednick has confirmed the mechanism that enables the brain to consolidate memory and found that a commonly prescribed sleep aid enhances the process.

13 Mar 2013

EDTA chelation, high-dose vitamins/minerals may provide additional benefit for MI patients

Heart attack patients given a combination of high-dose oral vitamins and minerals do not exhibit a significant reduction in recurrent cardiac events, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.

13 Mar 2013

Trial evaluates ranolazine in patients with diabetes, coronary artery disease and angina

A commonly used anti-anginal drug reduces chest pain in patients with type 2 diabetes and appears to have a more pronounced effect in those with poorer glucose control, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.

13 Mar 2013

RELAX study finds no beneficial effects of erectile dysfunction drug for diastolic heart failure

Despite high expectations for a commonly used erectile dysfunction drug to treat patients with diastolic heart failure, no beneficial effects were found in a study presented today at the American College of Cardiology's 62nd Annual Scientific Session.

13 Mar 2013

Lithera commences LIPO-202 Phase 2b trial for reduction of subcutaneous fat

Lithera, Inc., a clinical stage pharmaceutical company focused on lifestyle and medical indications in aesthetic medicine and ophthalmology, announced today that the first patient has been treated with LIPO-202 (Salmeterol Xinafoate for Injection) in its 500-patient Phase 2b "RESET" trial.

12 Mar 2013

Aliskiren and standard therapy not associated with reduced CV death or HF rehospitalization

Among patients hospitalized for heart failure (HF) with reduced left ventricular ejection fraction (LVEF; a measure of how well the left ventricle of the heart pumps with each contraction), initiation of the medication aliskiren in addition to standard therapy did not reduce cardiovascular death or HF rehospitalization at 6 or 12 months after discharge, according to a study published online by JAMA.

12 Mar 2013

Results from Orion Pharma’s ORM-12741 phase IIa study on AD

A new drug may improve memory problems in people with moderate Alzheimer's disease, according to a phase IIa study released today that will be presented at the American Academy of Neurology's 65th Annual Meeting in San Diego, March 16 to 23, 2013. The drug is called ORM-12741.

12 Mar 2013

Addition of niacin to statin does not improve HDL function

While two large clinical trials recently showed that adding niacin to statin therapy failed to improve clinical outcomes despite a significant increase in HDL-C levels, little is known about exactly why the increased HDL-C levels did not reduce the risk of cardiovascular events, including heart attack and stroke.

12 Mar 2013

$Sildenafil does not improve exercise capacity in HF patients with preserved ejection fraction$

Sildenafil does not improve exercise capacity in HF patients with preserved ejection fraction

Among patients with heart failure with preserved ejection fraction (a measure of heart function), administration of sildenafil for 24 weeks, compared with placebo, did not result in significant improvement in exercise capacity or clinical status, according to a study published online by JAMA.

12 Mar 2013

$Sildenafil does not help heart failure patients with preserved ejection fraction$

Sildenafil does not help heart failure patients with preserved ejection fraction

A commonly used erectile dysfunction drug, sildenafil, doesn't help patients who have heart failure with preserved ejection fraction, a condition in which the heart's lower chambers are stiff and cannot relax and fill fully between beats.

12 Mar 2013

Study identifies why prazosin may cause lightheadedness and fainting

A new study led by a Canadian research team has identified the reason why prazosin, a drug commonly used to reduce high blood pressure, may cause lightheadedness and possible fainting upon standing in patients with normal blood pressure who take the drug for other reasons, such as the treatment of PTSD and anxiety.

12 Mar 2013

Placebo News and Research

Interventional endovascular therapy is safe but does not improve MS outcomes: Study

Luminex collaborates with Merck to design companion diagnostic device for Alzheimer’s disease

Promising studies for Parkinson's to be presented at 65th AAN meeting

Researchers show inhibiting brain's filter can boost performance for tasks

Results from GTx's Phase 2 clinical trial of enobosarm published online

Phase 1b study of olesoxime initiated in multiple sclerosis (MS) patients

Researchers show vitamin D supplementation may help African-Americans lower blood pressure

ASTRONAUT trial finds no beneficial effects of aliskiren in recently hospitalized heart failure patients

Eplerenone may also reduce risk of heart failure, shows REMINDER trial

Research findings could lead to new sleep therapies to improve memory disorders

EDTA chelation, high-dose vitamins/minerals may provide additional benefit for MI patients

Trial evaluates ranolazine in patients with diabetes, coronary artery disease and angina

RELAX study finds no beneficial effects of erectile dysfunction drug for diastolic heart failure

Lithera commences LIPO-202 Phase 2b trial for reduction of subcutaneous fat

Aliskiren and standard therapy not associated with reduced CV death or HF rehospitalization

Results from Orion Pharma’s ORM-12741 phase IIa study on AD

Addition of niacin to statin does not improve HDL function

Sildenafil does not improve exercise capacity in HF patients with preserved ejection fraction

Sildenafil does not help heart failure patients with preserved ejection fraction

Study identifies why prazosin may cause lightheadedness and fainting

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News